Chronic obstructive pulmonary disease
Conditions
Interventions
Experimental treatment group and placebo control group:Aminophylline 4ml (500mg)+ 0.9% sodium chloride solution 250ml ivdrip Qd for 5 days versus placebo
Sponsors
Guangzhou 1st People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. More than or equal to 18 years old, male or female; 2. In line with the gold of chronic obstructive pulmonary disease diagnosis; 3. In COPD acute exacerbation period (symptom change degree more than the daily variation range, and lead to drug treatment programs change] patients; 4. Agreed and signed a written informed consent to the test.
Exclusion criteria
Exclusion criteria: 1. In addition to COPD lung diseases such as bronchial asthma, pneumonia, pulmonary tuberculosis, lung cancer, bronchiectasis and interstitial lung disease, pulmonary atelectasis, pulmonary abscess, empyema, cystic fibrosis, granulomatous disease, occlusion of lung disease bronchiolitis or recent pulmonary embolism; 2. With cilia dyskinesia, virus infection after bronchial overreaction syndrome, vocal cord dysfunction, sinusitis or reactive airway dysfunction syndrome patients; 3. There are pneumothorax, thoracic deformity, rib fracture, unstable heart function (such as the recent occurrence of myocardial infarction, unstable angina) or unstable vital signs of the patients; 4. Those suffering or have suffered from allergic rhinitis, allergic dermatitis and other allergic diseases; 5. Patients with malignant tumors, who underwent lobectomy, received lung or heart transplantation; 6. Serious illness requiring the use of mechanical ventilation (with at least the following: pH no more than 7.25; severe dyspnea with clinical signs of respiratory muscle fatigue or increased work of breathing, or all two, such as the use of accessory respiratory muscle, abdominal contradiction movement or intercostal space depression; heart rate 100U/L), renal insufficiency (creatinine 2mg/dl or more than 177 mol/l) or blood system diseases; 9. Immune damage, including HIV (AIDS, CD40.2g/ days; 13. Mental illness and the inability to cooperate with the lung function test; 14. In pregnancy or lactation women, pregnancy or breast-feeding women; 15. Participated in other clinical trials in the last months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of stay in hospital;CAT score; | — |
Countries
China
Contacts
Public ContactZiwen Zhao
Outcome results
None listed